What Impact Will CA's New “Transaction Review” Law Have?

The latest stories trending on MedCity News.

Editor's Pick

Top Story What Impact Will California's New "Transaction Review" Law Have? California passed a law last year aimed at controlling rising healthcare costs that gave the state the ability to scrutinize healthcare deals of a certain size involving California companies. What impact can it have?  Sponsored Content Importance of Patient Capital in Life Sciences Presented by TSX Venture Exchange TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development purposes. Learn More>> Have A Moment? What would you like to see more of on MedCity News? What would you like to see less of? How can we serve you better? Please take a quick 3-5 minutes of your time and tell us what you think. As a thank you for your time you can enter to win a $250 gift card. Take Survey Now

Featured News

Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark's science comes University of Copenhagen research on a novel fat cell target. Streamlining Healthcare Insurers' Processes: Unlocking Efficiency and Collaboration for Enhanced Outcomes While the recent rollbacks of authorization requirements by insurers are a positive step forward, there is still work to be done in streamlining processes and reducing administrative burdens in the healthcare industry. CMS Requires States To Assess Medicaid Disenrollment Process Some states may not be following federal requirements for the Medicaid renewal process, resulting in many individuals being wrongly removed from coverage, CMS said. Children may especially be affected. Strive Health, Oak Street Health Strike Kidney Care Partnership Kidney care company Strive Health announced last week that it is collaborating with primary care company Oak Street Health to serve Medicare members with stage 4 chronic kidney disease and end-stage kidney disease. The Inflation Reduction Act's Impact on Drug Development for Rare Diseases Despite these wins for many patients, the new law is already impacting the discovery and development of new drugs for people living with orphan diseases. Not only are drugs that could treat more than one disease being disincentivized, small molecule medicines, which play an important role in treating neurological disorders, cancers, and other diseases, may also be disadvantaged by the law.

Resources

The Future of Healthcare CIOs Learn how successful CIOs are adapting to challenging times and how they might shift their roles in response to exciting innovation in the years to come. Download Now

MedCity News • PO Box 901 • New York, NY unsubscribe